A61P 43 - Drugs for specific purposes, not provided for in groups

Patents for A61P 43 - Drugs for specific purposes, not provided for in groups (156,317)
10/2002
10/24/2002	WO2002083873A2 Enzymes
10/24/2002	WO2002083870A2 Pufa polyketide synthase systems and uses thereof
10/24/2002	WO2002083858A2 Methods to inhibit viral replication
10/24/2002	WO2002083847A2 Cdna encoding the human alpha2 delta4 calcium channel subunit
10/24/2002	WO2002083736A2 G-protein coupled receptor molecules and uses thereof
10/24/2002	WO2002083727A2 Nucleic acid sequences of hyperplasies and tumors of the thyroid
10/24/2002	WO2002083720A2 Intermediates and enzymes of the non-mevalonate isoprenoid pathway
10/24/2002	WO2002083714A2 Method and system for optimizing multi-epitope nucleic acid constructs and peptides encoded thereby
10/24/2002	WO2002083711A2 Molecular mimetics of meningococcal b epitopes which elicit functionally active antibodies
10/24/2002	WO2002083709A2 Kinases and phosphatases
10/24/2002	WO2002083704A1 Vascular endothelial growth factor 2
10/24/2002	WO2002083693A1 Thiazolopyrimidines and their use as modulators of chemokine receptor activity
10/24/2002	WO2002083684A1 Novel pyridine- and cyclohexenyl-comprising pyrrolobenzodiazepi ne-carboxamides and derivatives thereof; tocolytic oxytocin receptor antagonists
10/24/2002	WO2002083681A1 Novel cyclohexenyl phenyl diazepines vasopressin and oxytocin receptor modulators
10/24/2002	WO2002083680A1 Novel tricyclic hydroxy carboxamides and derivatives thereof tocolytic oxytocin receptor antagonists
10/24/2002	WO2002083679A1 Novel hydroxy cyclohexenyl phenyl carboxamides tocolytic oxytocin receptor antagonists
10/24/2002	WO2002083678A1 Tricyclic diazepines as tocolytic oxytocin receptor antagonists
10/24/2002	WO2002083674A2 Compositions containing imidazotriazinone for nasal application
10/24/2002	WO2002083673A1 1,3,8-triazaspiro[4.5]decan-4-one derivatives useful for the treatment of orl-1 receptor mediated disorders
10/24/2002	WO2002083671A1 Mercaptoacetylamide derivatives, a process for their preparation and their use
10/24/2002	WO2002083669A1 Tropane alkaloid multidrug resistance inhibitors from erythroxylum pervillei and use of the same
10/24/2002	WO2002083668A1 Isoxaxole derivatives as inhibitors of src and other protein kinases
10/24/2002	WO2002083667A2 Inhibitors of c-jun n-terminal kinases (jnk) and other protein kinases
10/24/2002	WO2002083666A1 Substituted benzofuran-2-carboxamides derivatives
10/24/2002	WO2002083665A1 DIHYDRO-BENZO[b][1,4]DIAZEPIN-2-ONE DERIVATIVES AS MGLUR2 ANTAGONISTS I
10/24/2002	WO2002083664A1 3-substituted quinoline-4-carboxamide derivatives as nk-3 and nk-2 receptor antagonists
10/24/2002	WO2002083663A1 Quinoline-4-carboxamide derivatives as nk-3 and nk-2 receptor antagonists
10/24/2002	WO2002083660A1 Remedies
10/24/2002	WO2002083658A1 Piperazine-benzamide derivatives useful as apob-100 and/or mtp inhibitor
10/24/2002	WO2002083657A2 Broadspectrum 2-(substituted-amino)-benzothiazole sulfonamide hiv protease inhibitors
10/24/2002	WO2002083656A2 5-membered heterocycles, preparation and use thereof as mao inhibitors and lipid peroxidation inhibitors, preparation thereof and use thereof as medicaments
10/24/2002	WO2002083655A1 Prodrugs of cox-2 inhibitors
10/24/2002	WO2002083652A1 DIHYDRO-BENZO [b] [1, 4] DIAZEPIN-2-ONE DERIVATIVES AS MGLUR2 ANTAGONISTS II
10/24/2002	WO2002083648A1 Novel 1h-indazole compound
10/24/2002	WO2002083645A1 Novel compounds
10/24/2002	WO2002083643A1 Phenyl heterocyclyl ether derivatives as serotonin re-uptake inhibitors
10/24/2002	WO2002083642A1 Compounds useful as anti-inflammatory agents
10/24/2002	WO2002083632A1 Anilide and cyclodextrin complexes, their preparation and their use as medicine in particular for treating dyslipidemiae
10/24/2002	WO2002083628A1 1,4-disubstituted benzo-fused compounds
10/24/2002	WO2002083627A2 Ligands des integrins avss6
10/24/2002	WO2002083624A1 3,4-di-substituted cyclobutene-1,2-diones as cxc-chemokine receptor ligands
10/24/2002	WO2002083616A1 α-SUBSTITUTED φ-ARYLFATTY ACID DERIVATIVE
10/24/2002	WO2002083241A1 Single dose aromatase inhibitor for treating infertility
10/24/2002	WO2002083240A1 Aromatase inhibition to enhance assisted reproduction
10/24/2002	WO2002083186A1 Nuclear receptor-mediated introduction of a pna into cell nuclei
10/24/2002	WO2002083184A2 Gene therapy with chimeric oligonucleotides delivered by a method comprising a step of iontophoresis
10/24/2002	WO2002083180A1 Elongated and multiple spacers in activatible prodrugs
10/24/2002	WO2002083179A2 Fusion proteins
10/24/2002	WO2002083175A1 Visual function improving agents
10/24/2002	WO2002083168A1 Enzymes combination coadjuvating in the interferon therapy
10/24/2002	WO2002083166A1 Interferon-polymer complexes and medicinal use thereof
10/24/2002	WO2002083163A1 The use of the protein uk114 for the treatment and the prevention of chronic active hepatitis
10/24/2002	WO2002083159A1 Palliative effects of morinda citrifolia oil and juice
10/24/2002	WO2002083158A1 Method for preparing an extract of ginkgo biloba leaves highly enriched in active principles
10/24/2002	WO2002083152A1 Activation of natural killer cells by adenosine a3 receptor agonists
10/24/2002	WO2002083149A1 Drugs fo rpromoting the proliferation, differentiation and/or survival of glial cells containing cyclic phosphatidic acid
10/24/2002	WO2002083148A1 Nerve cell survival promoters containing cyclic phosphatidic acid derivative
10/24/2002	WO2002083147A1 Use of bile acid or bile salt fatty acid conjugates
10/24/2002	WO2002083143A1 Cxcr3 antagonists
10/24/2002	WO2002083141A1 Treatment of fibromyalgia and chronic fatigue syndrome
10/24/2002	WO2002083134A1 Aryl and biaryl piperidines used as mch antagonists
10/24/2002	WO2002083128A1 2,1-oxazoline and 1,2-pyrazoline-based inhibitors of dipeptidyl peptidase iv and method
10/24/2002	WO2002083127A1 Protein modification-inhibitory compositions
10/24/2002	WO2002083125A1 Method of inhibiting adhesion formation
10/24/2002	WO2002083123A1 Aurones as telomerase inhibitors
10/24/2002	WO2002083121A1 Compositions for improving skin environment and clothes thereof
10/24/2002	WO2002083120A2 Medium-chain length fatty acids, glycerides and analogues as neutrophil survival and activation factors
10/24/2002	WO2002083115A1 Treatment of disorders secondary to organic impairments
10/24/2002	WO2002083113A2 Aerosol compositions containing formoterol and a steroid such as e.g. budesonide or fluticasone for delivery into the lungs via nebulization
10/24/2002	WO2002083111A2 Imidazole, thiazole and oxazole derivatives and their use for the manufacture of a medicament for the treatment and/or prevention of pollakiuria or urinary incontinence
10/24/2002	WO2002083108A2 Compositions containing cgmp pde inhibitors and local anaesthetic agents for nasal application
10/24/2002	WO2002083106A1 Controlled delivery of tetracycline compounds and tetracycline derivatives
10/24/2002	WO2002083083A2 Pharmaceutically active compounds and methods of use
10/24/2002	WO2002083067A2 Prodrugs via acylation with cinnamate
10/24/2002	WO2002083065A2 Peptide antiangiogenic drugs
10/24/2002	WO2002083064A2 A method of treating cancer
10/24/2002	WO2002083060A2 Use of amino acid transporter atb0,+ as a delivery system for drugs and prodrugs
10/24/2002	WO2002083058A2 Anti-inflammatory fatty alcohols and fatty acid esters useful as antigen carriers
10/24/2002	WO2002074763A9 Benzimidazol derivatives modulate chemokine receptors
10/24/2002	WO2002066035A3 Azoles as malonyl-coa decarboxylase inhibitors useful as metabolic modulators
10/24/2002	WO2002064557A3 New crystal forms of oxcarbazepine and processes for their preparation
10/24/2002	WO2002060931A3 A fimbria-like gene in bifidobacteria
10/24/2002	WO2002051848A3 Sulfamidothienopyrimidines and the use of the same as phosphodiesterase v inhibitors
10/24/2002	WO2002050065A3 Pyrazole compounds useful as protein kinase inhibitors
10/24/2002	WO2002047667A3 Novel medicament compositions based on anticholinesterase drugs and on a steroid
10/24/2002	WO2002040038A3 M. tuberculosis chaperonin 10 and uses thereof
10/24/2002	WO2002040015A8 Protein prenyl transferase inhibitors in the treatment of neuroinflammatory disease
10/24/2002	WO2002032397A9 Electroprocessing in drug delivery and cell encapsulation
10/24/2002	WO2002024659A3 Substituted imidazoles as dual histamine h1 and h3 agonists or antgonists
10/24/2002	WO2002011771A3 Contrast medium consisting of geometrically highly ordered proteins for medical diagnostics
10/24/2002	WO2002006462A3 Methylated nucleotide regulation of upa gene expression
10/24/2002	WO2002003972A3 Therapeutic and prophylactic use of reduced forms of pharmaceutical compounds
10/24/2002	WO2002000650A3 Novel compounds possessing antibacterial, antifungal or antitumor activity
10/24/2002	WO2002000210A3 Use of agents capable of reducing uric acid levels for the treatment of cardiovascular disease
10/24/2002	WO2001085206A3 Immunosuppressive compositions comprising an immunophilin-binding compound and a gingkolide compound
10/24/2002	WO2001068135A9 Compositions and methods for affecting osteogenesis
10/24/2002	WO2001059103A9 Method and reagent for the modulation and diagnosis of cd20 and nogo gene expression
10/24/2002	WO2000040247A9 2-oxy-benzoxazinone derivatives for the treatment of obesity
10/24/2002	US20020156585 Crystallization and structure determination of Staphylococcus aureus UDP-N-acetylenolpyruvylglucosamine reductase (S. aureus MurB)
10/24/2002	US20020156292 Anticancer agents

1 ... 871 872 873 874 875 876 877 878 879 880 881 882 883 884 885 886 887 888 889 890 891 ... 1564